Reported about 23 hours ago
Intellia Therapeutics presented promising three-year follow-up data from its Phase 1 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 participants remained attack-free for a median of 23 months post-treatment, showing a 98% reduction in monthly HAE attacks. The ongoing Phase 3 HAELO trial is progressing well, with Intellia aiming for a BLA submission in 2026 and a potential product launch in 2027.
Source: YAHOO